Affinity Asset Advisors’s NewAmsterdam Pharma Warrant NAMSW Stock Holding History

Affinity Asset Advisors’s Portfolio NAMSW Stock Details NAMSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.34M	Hold	245,000	–	–	0.24%	76
2026 Q1	$4.91M	Hold	245,000	–	–	0.25%	67
2025 Q4	$5.63M	Hold	245,000	–	–	0.32%	61
2025 Q3	$4.19M	Hold	245,000	–	–	0.37%	57
2025 Q2	$1.96M	Buy	245,000 +3,043	+1%	+$25.3K	0.27%	57
2025 Q1	$2.75M	Buy	241,957 +4,022	+2%	+$43.9K	0.26%	58
2024 Q4	$3.33M	Buy	237,935 +24,961	+12%	+$270K	0.45%	46
2024 Q3	$1.49M	Buy	212,974 +10,375	+5%	+$80.5K	0.2%	68
2024 Q2	$1.92M	Hold	202,599	–	–	0.22%	65
2024 Q1	$2.24M	Buy	202,599 +65,599	+48%	+$597K	0.28%	72
2023 Q4	$429K	Hold	137,000	–	–	0.08%	75
2023 Q3	$260K	Buy	137,000 +100,000	+270%	+$194K	0.07%	78
2023 Q2	$77.3K	Hold	37,000	–	–	0.03%	68
2023 Q1	$68.5K	Buy	+37,000	New	+$58.7K	0.02%	71

Other funds holding NAMSW

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Vestcor Inc Fredericton, New Brunswick, Canada $4.05B AUM 34.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Affinity Asset Advisors's NAMSW Position: Q2 2026 in Review

Affinity Asset Advisors held its NewAmsterdam Pharma Warrant (NAMSW) position steady in Q2 2026 at 245,000 shares worth $5.34M. The position accounts for 0.24% of the portfolio, ranked #76.

Affinity Asset Advisors first reported a position in NAMSW in Q1 2023 and has held it in 14 quarters since. The position peaked at $5.63M in Q4 2025. 9 funds tracked by Wall St. Rank hold NAMSW as of Q2 2026.

Affinity Asset Advisors held 245,000 shares of NewAmsterdam Pharma Warrant worth $5.34M as of Q2 2026.
Affinity Asset Advisors left its NewAmsterdam Pharma Warrant share count unchanged in Q2 2026.
NewAmsterdam Pharma Warrant made up 0.24% of Affinity Asset Advisors's portfolio in Q2 2026, its #76 holding.
Affinity Asset Advisors first reported a position in NewAmsterdam Pharma Warrant in Q1 2023 and has held it in 14 quarters since.
Affinity Asset Advisors's NewAmsterdam Pharma Warrant position peaked at $5.63M in Q4 2025.
9 funds tracked by Wall St. Rank held NewAmsterdam Pharma Warrant as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.